

## Microbial Etiology of Travelers' Diarrhea in Mexico, Guatemala, and India: Importance of Enterotoxigenic *Bacteroides fragilis* and *Arcobacter* Species<sup>∇</sup>

Zhi-Dong Jiang,<sup>1\*</sup> Herbert L. DuPont,<sup>1,2,3,4</sup> Eric L. Brown,<sup>1</sup> Ranjan K. Nandy,<sup>5</sup>  
Thandavaryan Ramamurthy,<sup>5</sup> Anuradha Sinha,<sup>5</sup> Santanu Ghosh,<sup>5</sup>  
Sucharita Guin,<sup>5</sup> Kaur Gurleen,<sup>6</sup> Savio Rodrigues,<sup>6</sup>  
Jacklyn J. Chen,<sup>2</sup> Robin McKenzie,<sup>7</sup>  
and Robert Steffen<sup>8</sup>

The University of Texas School of Public Health,<sup>1</sup> the University of Texas Medical School at Houston,<sup>2</sup> Baylor College of Medicine,<sup>3</sup> and St. Luke's Episcopal Hospital,<sup>4</sup> Houston, Texas; National Institute of Cholera and Enteric Diseases, Kolkata, India<sup>5</sup>; Goa Medical College, Bambolim Goa, India<sup>6</sup>; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland<sup>7</sup>; and Institute of Social and Preventive Medicine of the University of Zurich, Zurich, Switzerland<sup>8</sup>

Received 1 September 2009/Returned for modification 19 October 2009/Accepted 20 November 2009

**This study examined established enteric pathogens, *Arcobacter* species and enterotoxigenic *Bacteroides fragilis* (ETBF), in 201 U.S. and European travelers with acute diarrhea acquired in Mexico, Guatemala, and India. *Arcobacter butzleri* and ETBF were detected in 8% and 7% of diarrhea cases, respectively.**

Etiology studies of travelers' diarrhea (TD) have identified diarrheagenic *Escherichia coli* as the most important cause (>50%) of illness. However, 20 to 40% of subjects remain without a definable cause (5, 6), and antibiotics shorten TD illness without an identified pathogen (2–4), suggesting the presence of occult bacterial enteropathogens.

*Bacteroides fragilis* strains are part of the normal colonic flora in adults (16). A subclass of *B. fragilis* that secretes a 20-kDa proinflammatory zinc-dependent metalloprotease toxin has been defined as enterotoxigenic *B. fragilis* (ETBF). The strains have been recognized as a cause of acute diarrhea in pediatric and adult populations in regions of endemicity (24).

*Arcobacter* species are considered emerging food-borne pathogens (9). At present, six species of *Arcobacter* have been characterized, of which *A. butzleri*, *A. cryaerophilus*, *A. skirrowii*, and *A. cibarius* are human- or animal-related pathogens (10). *Arcobacters* seem not to belong to the normal intestinal flora of humans, but their role in pathogenicity remains unknown (10).

(This work was presented at the International Society of Travel Medicine Conference, Budapest, Hungary, May 2009.)

The population included 201 U.S. and European travelers to Mexico, Guatemala, and India who took part in an ongoing clinical trial. Acute diarrhea was defined as  $\geq 3$  unformed stools in 24 h accompanied by one or more gastrointestinal symptoms. Stool samples collected before antibiotic usage were examined for the prevalence of enteric pathogens (12).

Twenty *E. coli* colonies from each stool culture were

screened for enterotoxigenic *E. coli* (EPEC) by showing that the organism produced heat-labile enterotoxin (LT) and/or heat-stable enterotoxin (ST) by PCR (15). Five of the 20 isolated *E. coli* colonies were tested for the presence of enterotoxigenic *E. coli* (EPEC) by a HEp-2 assay (18).

All stool samples from study sites were cultured for conventional bacterial enteric pathogens, including *Shigella* species, *Salmonella* species, *Vibrio* species, *Campylobacter jejuni*, *Yersinia enterocolitica*, *Aeromonas* species, and *Plesiomonas shigelloides* using previously reported methods (12).

Genomic DNA was extracted from all stools, and PCR was used to target the 16S and 23S rRNA genes of *A. butzleri*, *A. skirrowii*, and *A. cryaerophilus* and the *B. fragilis* toxin (*bft*) gene for ETBF detection (11, 24).

Seventy-six percent of diarrhea stool samples (152/201) tested were EPEC positive, with ST being the primary toxin found for 102 (51%) of subjects (Table 1). The importance of EPEC and specific toxin patterns of the isolates differed by geographic location (Table 1).

Stool samples from a total of 16/201 (8%) patients were positive for *Arcobacter* spp. by PCR detection from diarrhea stools (Table 1). All 16S and 23S rRNA genes of *Arcobacter*-positive stool samples were detected as *A. butzleri*. No other *Arcobacter* spp. were detected. Fifteen subjects had positive ETBF stool samples from 201 diarrhea stool samples (7%), ranging from 13% (6/48) in Goa to 4% (1/25) in Guatemala (Table 1).

At least one enteropathogen was found for 168/201 (84%) patients (Table 1). *A. butzleri* coexisting with EPEC accounted for infection of 13/16 patients. Six of 13 patients with EPEC and *A. butzleri* were detected in Goa, India. For 2/16 patients with *A. butzleri* detected, *Campylobacter* was also identified (data not shown). Seven of 15 patients with TD had both ETBF and EPEC detected. Among the other enteric pathogens identified in the tested specimens, the most frequently

\* Corresponding author. Mailing address: Center for Infectious Diseases, University of Texas School of Public Health, 1200 Herman Pressler Room 741, Houston, TX 77030. Phone: (713) 500-9371. Fax: (713) 500-9364. E-mail: zhi-dong.jiang@uth.tmc.edu.

<sup>∇</sup> Published ahead of print on 27 January 2010.

TABLE 1. Prevalence of enteric pathogens in stools of subjects with travelers' diarrhea acquired in Mexico, Guatemala, or India

Area of isolation	No. of Subjects	Study period(s)	No. (%) of isolates with detection of:														
			ETEC			ETEC mixed with <i>A. butzleri</i>	ETBF	ETEC mixed with ETBF	<i>Aeromonas</i> spp.	<i>Campylobacter</i> spp.	<i>Plesiomonas shigelloides</i>	<i>Salmonella</i> spp.	<i>Shigella</i> spp.	<i>Vibrio</i> spp.	<i>Yersinia enterocolitica</i>	No pathogen	Multiple pathogens
			ST	LT	ST/ILT												
Goa, India	48	January 2007–April 2007, December 2007–April 2008	29 (60)	3 (6)	4 (8)	2 (4)	3 (6)	3 (6)	13 (27)	4 (8)	2 (4)	6 (13)	2	0	3 (6)	29 (60)	
Kolkata, India	36	January 2008–August 2008	10 (28)	3 (8)	0	9 (25)	1 (3)	0	4 (11)	0	0	2 (6)	0	0	8 (22)	10 (28)	
Antigua, Guatemala	25	June 2007–January 2008	15 (60)	1 (4)	2 (8)	2 (8)	3 (12)	1 (4)	1 (4)	0	1 (4)	0	1 (4)	0	4 (16)	8 (32)	
Cuernavaca, Mexico	57	June 2008–August 2008	29 (51)	9 (16)	1 (2)	5 (9)	1 (2)	4 (7)	1 (2)	0	2 (4)	0	0	0	12 (21)	13 (23)	
Guadalajara, Mexico	35	June 2008–August 2008	19 (54)	4 (11)	0	5 (14)	0	3 (9)	0	0	1 (3)	0	0	0	6 (17)	11 (31)	
Total	201		102 (51)	20 (10)	7 (3)	23 (11)	8 (4)	16 (8)	19 (9)	4 (2)	5 (2)	8 (4)	3 (1)	0	33 (16)	71 (35)	

isolated organisms were *Campylobacter* spp. (9%; 19/201 subjects), followed by *Shigella* spp. (4%; 8/201), *Salmonella* spp. (2%; 5/201), *Aeromonas* spp. or *Plesiomonas* spp. (2%; 4/201), and *Vibrio* spp. (1%; 3/201). *Yersinia enterocolitica* was not identified.

We examined 20 *E. coli* colonies per diarrheal stool sample for ETEC identification, which resulted in a high rate of identification. Clearly, the more colonies studied, the greater likelihood of detecting ETEC (8). To our knowledge, this level of pathogen detection, up to 94% (Goa) of stool samples, has never been reported for studies of TD. As a result, we recommend that more than five *E. coli* colonies be screened when the detection of ETEC is being sought for subjects with TD.

To our knowledge, this is the first study demonstrating *Arcobacter* spp. and ETBF associated with TD. Since its discovery in 1977, *A. butzleri* and *A. cryaerophilus* have been found in stool samples of patients with acute diarrhea (1, 7, 13, 14). A recent study (22) found a 7% *A. butzleri*-positive rate for children with diarrhea, and 55% of *A. butzleri* cases had elevated lactoferrin levels, indicating possible inflammation. Wybo et al. reported the first isolation of *A. skirrowii* from a patient with chronic diarrhea (25). Because the codetection of *A. butzleri* and ETEC was common (13/16 patients), it was not possible to define *A. butzleri* as the causative agent of infection of these patients. ETBF also tended to occur in subjects infected with ETEC isolates, which was seen for 7/15 subjects. Further studies of mixed infections will be needed to determine the contribution of *Arcobacter* and *B. fragilis* to diarrhea cases and to determine the interrelationship between *Arcobacter*, *B. fragilis*, and ETEC in mixed infections.

ETBF is an emerging enteric pathogen associated with diarrheal diseases in children, adults, and animals (17, 19, 24). Sack et al. (20, 21) reported that 12% of isolates from native Americans and 9% of isolates from Bangladeshi children were ETBF positive, compared to 6% of the controls. San Joaquin et al. (23) found a strong association between diarrheal disease and the presence of ETBF in feces of children (isolation rate of 4.8%), whereas *B. fragilis* strains were recovered for 32.1% of children with diarrhea in an urban setting in the United States. In this study, we applied PCR methodology to investigate the presence of ETBF directly in fecal samples. The *B. fragilis* enterotoxin gene (*bft*) was detected from diarrheal stool samples by PCR for 13% of patients with TD in Goa, India. A low recovery rate of ETBF in Guatemala was observed (4%).

PCR-based methods have been described for the direct detection of other bacterial enteropathogens, including *Shigella*, *Salmonella*, and *Campylobacter* species, with the goals of increasing sensitivity and speed of identification. The major problem encountered with PCR-based detection systems for stool samples is that no bacterial isolates are obtained, limiting further studies. Future studies of TD should include conventional pathogens, such as ETEC, EAEC, *Arcobacter*, and ETBF, to better define their geographic importance and potential role in causing TD.

This work was supported in part by discretionary funds from the University of Texas School of Public Health and Public Health Service grant DK56338, which funds the Digestive Diseases Center of Texas Medical Center.

We disclose no conflict of interest regarding the manuscript.

## REFERENCES

1. Burnens, A. P., P. Boss, F. Orskov, I. Orskov, U. B. Schaad, F. Muller, R. Heinze, and J. Nicolet. 1992. Occurrence and phenotypic properties of verotoxin producing *Escherichia coli* in sporadic cases of gastroenteritis. *Eur. J. Clin. Microbiol. Infect. Dis.* **11**:631–634.
2. DuPont, H. L., C. D. Ericsson, J. J. Mathewson, F. J. de la Cabada, and D. A. Conrad. 1992. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. *JAMA* **267**:1932–1935.
3. DuPont, H. L., C. D. Ericsson, J. J. Mathewson, and M. W. DuPont. 1992. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. *Antimicrob. Agents Chemother.* **36**:87–91.
4. DuPont, H. L., R. Haake, D. N. Taylor, C. D. Ericsson, Z. D. Jiang, P. C. Okhuysen, and R. Steffen. 2007. Rifaximin treatment of pathogen-negative travelers' diarrhea. *J. Travel Med.* **14**:16–19.
5. Dupont, H. L., Z. D. Jiang, J. Belkind-Gerson, P. C. Okhuysen, C. D. Ericsson, S. Ke, D. B. Huang, M. W. Dupont, J. A. Adachi, F. J. De La Cabada, D. N. Taylor, S. Jaini, and F. Martinez Sandoval. 2007. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. *Clin. Gastroenterol. Hepatol.* **5**:451–456.
6. DuPont, H. L., R. R. Reves, E. Galindo, P. S. Sullivan, L. V. Wood, and J. G. Mendiola. 1982. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. *N. Engl. J. Med.* **307**:841–844.
7. Engberg, J., S. L. On, C. S. Harrington, and P. Gerner-Smidt. 2000. Prevalence of *Campylobacter*, *Arcobacter*, *Helicobacter*, and *Sutterella* spp. in human fecal samples as estimated by a reevaluation of isolation methods for campylobacters. *J. Clin. Microbiol.* **38**:286–291.
8. Galbadage, T., Z. D. Jiang, and H. L. DuPont. 2009. Improvement in detection of enterotoxigenic *Escherichia coli* in patients with travelers' diarrhea by increasing the number of *E. coli* colonies tested. *Am. J. Trop. Med. Hyg.* **80**:20–23.
9. Gonzalez, A., S. Botella, R. M. Montes, Y. Moreno, and M. A. Ferrus. 2007. Direct detection and identification of *Arcobacter* species by multiplex PCR in chicken and wastewater samples from Spain. *J. Food Prot.* **70**:341–347.
10. Houf, K., and R. Stephan. 2007. Isolation and characterization of the emerging foodborne pathogen *Arcobacter* from human stool. *J. Microbiol. Methods* **68**:408–413.
11. Houf, K., A. Tutenel, L. De Zutter, J. Van Hoof, and P. Vandamme. 2000. Development of a multiplex PCR assay for the simultaneous detection and identification of *Arcobacter butzleri*, *Arcobacter cryaerophilus* and *Arcobacter skirrowii*. *FEMS Microbiol. Lett.* **193**:89–94.
12. Jiang, Z. D., B. Lowe, M. P. Verenkar, D. Ashley, R. Steffen, N. Tornieporth, F. von Sonnenburg, P. Waiyaki, and H. L. DuPont. 2002. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). *J. Infect. Dis.* **185**:497–502.
13. Kiehlbauch, J. A., D. J. Brenner, M. A. Nicholson, C. N. Baker, C. M. Patton, A. G. Steigerwalt, and I. K. Wachsmuth. 1991. *Campylobacter butzleri* sp. nov. isolated from humans and animals with diarrheal illness. *J. Clin. Microbiol.* **29**:376–385.
14. Lerner, J., V. Brumberger, and V. Preac-Mursic. 1994. Severe diarrhea associated with *Arcobacter butzleri*. *Eur. J. Clin. Microbiol. Infect. Dis.* **13**:660–662.
15. Meraz, I. M., Z. D. Jiang, C. D. Ericsson, A. L. Bourgeois, R. Steffen, D. N. Taylor, N. Hernandez, and H. L. DuPont. 2008. Enterotoxigenic *Escherichia coli* and diffusely adherent *E. coli* as likely causes of a proportion of pathogen-negative travelers' diarrhea—a PCR-based study. *J. Travel Med.* **15**:412–418.
16. Moore, W. E., and L. V. Holdeman. 1974. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. *Appl. Microbiol.* **27**:961–979.
17. Myers, L. L., B. D. Firehammer, D. S. Shoop, and M. M. Border. 1984. *Bacteroides fragilis*: a possible cause of acute diarrheal disease in newborn lambs. *Infect. Immun.* **44**:241–244.
18. Nataro, J. P., J. B. Kaper, R. Robins-Browne, V. Prado, P. Vial, and M. M. Levine. 1987. Patterns of adherence of diarrheagenic *Escherichia coli* to HEp-2 cells. *Pediatr. Infect. Dis. J.* **6**:829–831.
19. Pantosti, A., M. G. Menozzi, A. Frate, L. Sanfilippo, F. D'Ambrosio, and M. Malpeli. 1997. Detection of enterotoxigenic *Bacteroides fragilis* and its toxin in stool samples from adults and children in Italy. *Clin. Infect. Dis.* **24**:12–16.
20. Sack, R. B., M. J. Albert, K. Alam, P. K. Neogi, and M. S. Akbar. 1994. Isolation of enterotoxigenic *Bacteroides fragilis* from Bangladeshi children with diarrhea: a controlled study. *J. Clin. Microbiol.* **32**:960–963.
21. Sack, R. B., L. L. Myers, J. Almeida-Hill, D. S. Shoop, W. C. Bradbury, R. Reid, and M. Santosham. 1992. Enterotoxigenic *Bacteroides fragilis*: epidemiologic studies of its role as a human diarrhoeal pathogen. *J. Diarrhoeal Dis. Res.* **10**:4–9.
22. Samie, A., C. L. Obi, L. J. Barrett, S. M. Powell, and R. L. Guerrant. 2007. Prevalence of *Campylobacter* species, *Helicobacter pylori* and *Arcobacter* species in stool samples from the Venda region, Limpopo, South Africa: studies using molecular diagnostic methods. *J. Infect.* **54**:558–566.
23. San Joaquin, V. H., J. C. Griffis, C. Lee, and C. L. Sears. 1995. Association of *Bacteroides fragilis* with childhood diarrhea. *Scand. J. Infect. Dis.* **27**:211–215.
24. Sears, C. L., S. Islam, A. Saha, M. Arjumand, N. H. Alam, A. S. Faruque, M. A. Salam, J. Shin, D. Hecht, A. Weintraub, R. B. Sack, and F. Qadri. 2008. Association of enterotoxigenic *Bacteroides fragilis* infection with inflammatory diarrhea. *Clin. Infect. Dis.* **47**:797–803.
25. Wybo, I., J. Breynaert, S. Lauwers, F. Lindenburg, and K. Houf. 2004. Isolation of *Arcobacter skirrowii* from a patient with chronic diarrhea. *J. Clin. Microbiol.* **42**:1851–1852.